Ken Kelley is Chairman/CEO of PaxVax, a social biotech venture developing pill forms of vaccines. PaxVax business model is to run a for-profit in the First World supporting a non-profit in the Third World. Investors to date support this double bottom line model. PaxVax is currently raising a second round of capital to support clinical trials of its Swine Flu Pill vaccine. PaxVax is targeting influenza (Swine Flu H1N1, Bird Flu H5N1) as well as the world
Join the SOCAP Newsletter!